Feature | Genetic Testing | December 17, 2021

Diverse Genome Sequences Provide a Powerful Tool for Studying Risk of Heart Disease

Study of millions of people from diverse ancestral groups substantially improves identification of genomic variants associated with blood lipid levels

A large-scale NIH genetic testing study of people from diverse ancestries, researchers narrowed down the number of genomic variants that are strongly associated with blood lipid levels and generated a polygenic cardiovascular risk score to predict elevated low-density lipoprotein cholesterol levels. Getty Images

In a large-scale study of people from diverse ancestries, researchers narrowed down the number of genomic variants that are strongly associated with blood lipid levels and generated a polygenic risk score to predict elevated low-density lipoprotein cholesterol levels, a major risk factor for heart disease. The study, published in the journal Nature,[1] was led by the Global Lipids Genetics Consortium. The authors include researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH).  

Lipids are fat-like substances that can be found in blood and body tissues. They come in two major forms — cholesterol and triglycerides. Humans need a certain amount of lipids in the body for normal function, but elevated lipid levels may increase the risk of developing a heart condition. Polygenic risk scores provide an estimate of an individual’s risk for specific diseases, based on their DNA changes related to those diseases.

“Finding the set of genomic variants that are important for this trait is key for us to understand the biology and identify new drug targets,” said Cristen Willer, Ph.D., senior author and professor of human genetics at the University of Michigan, Ann Arbor. ”These genomic variants then inform how well polygenic risk scores work to determine risk for such diseases.”

Since the field’s inception, the genomics community has performed over 6,000 studies looking at the association of specific genomic variants and cardiovascular disease. However, the design of these studies overwhelmingly included individuals from European ancestral populations.

Genetic testing to assess cardiovascular risksTo address this issue, researchers accumulated data from 201 previous genome-wide association genetic testing studies, including about 1.65 million individuals from five ancestral groups: African, East Asian, European, Hispanic and South Asian. About 1.32 million of those studies were from European ancestry, and the remaining 350,000 were non-European. The studies contained data on blood levels of the different classes of cholesterol and triglycerides.

The research group calculated the polygenic risk scores using data from each of the different ancestral groups, either separately or all together. Then, they tested the risk scores in a diverse set of studies, including Africans enrolled from Ghana, Kenya and Nigeria as part of the Africa America Diabetes Mellitus study.[2] Charles Rotimi, Ph.D., scientific director of the NHGRI Intramural Research Program, was the principal investigator of the study.

The results showed a polygenic risk score that includes diverse genomic data is much more predictive of whether a person of any ancestry will have elevated low-density lipoprotein cholesterol levels than a score that only includes European genomic data.

“The message couldn’t be more clear. To have a fuller understanding of the effects of genomic variation on disease, we simply must include as many diverse groups of people as possible,” said Rotimi, a co-author on the paper. “It is the single biggest way by which we can ensure that the gains of genomic medicine and technologies are equitably deployed to serve the health needs of all human populations.”

For each ancestral group, the polygenic risk score that used data from all ancestries worked at least as well as or better than the risk scores derived from data from the same ancestral group.    

“These results show that our concerted effort to include many diverse groups of people in genomic research will yield benefits such as new therapeutics and prevention strategies that improve the health of all people,” said Cashell Jaquish, Ph.D., a genetic epidemiologist and program officer within the Division of Cardiovascular Sciences at the National Heart Lung, and Blood Institute.

Funding for the study was provided by the National Heart, Lung and Blood Institute, part of the National Institutes of Health. 

Learn more about basic research at the NIH: www.nih.gov/news-events/basic-research-digital-media-kit

NHGRI is one of the 27 institutes and centers at the National Institutes of Health. The NHGRI Extramural Research Program supports grants for research, and training and career development at sites nationwide. Additional information about NHGRI can be found at www.genome.gov.

Find more genetic testing content

Find more cardiology technology news

 

References:

1. Sarah E. Graham, Shoa L. Clarke, Kuan-Han H. Wu, et al. The power of genetic diversity in genome-wide association studies of lipids. Nature (2021). https://doi.org/10.1038/s41586-021-04064-3. Published online Dec. 9, 2021.

2. Charles N Rotimi, Guanjie Chen, Adebowale A Adeyemo, et al. A genome-wide search for type 2 diabetes susceptibility genes in West Africans: the Africa America Diabetes Mellitus (AADM) Study. Diabetes. 2004 Mar;53(3):838-41. doi: 10.2337/diabetes.53.3.838.

 

Related Content

Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
News | Cardiac Diagnostics

March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potential ...

Home March 08, 2021
Home
News | Cardiac Diagnostics

March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management ...

Home March 03, 2021
Home
Subscribe Now